Deborah J. Moonan, RN, BSN, Director, Continuing Education & Grants
Ms. Moonan has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education & Grants
Ms. Gianola has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Mazzaferro V, Regalia E, Doci R et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699.
Clavien PA, Lesurtel M, Bossuyt PM et al.. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11–22.
Yao FY, Bass NM, Nikolai B et al.. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873–883.
Yao FY, Bass NM, Nikolai B et al.. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684–692.
- Search Google Scholar
- Export Citation
. Yao FY Bass NM Nikolai B A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9: 684– 692.
Cucchetti A, Cescon M, Bigonzi E et al.. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011;17:1344–1354.
Maluf D, Fisher RA, Maroney T et al.. Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy. Am J Transplant 2003;3:312–317.
Mehta N, Dodge JL, Goel A et al.. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013;19:1343–1353.
Otto G, Herber S, Heise M et al.. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260–1267.
Vitale A, D’Amico F, Frigo AC et al.. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010;17:2290–2302.
Sala M, Fuster J, Llovet JM et al.. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004;10:1294–1300.
Mailey B, Artinyan A, Khalili J et al.. Evaluation of absolute serum alpha-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011;146:26–33.
Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013;19:634–645.
Merani S, Majno P, Kneteman NM et al.. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011;55:814–819.
Lai Q, Avolio AW, Graziadei I et al.. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013;19:1108–1118.
Yao FY, Kerlan RK Jr, Hirose R et al.. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819–827.
Yao FY, Mehta N, Fix OK et al.. Down-stating of hepatocellular carcinoma to within Milan criteria prior to liver transplantation: comparison of long-term outcomes with tumors meeting Milan criteria without requiring down-staging [abstract]. Hepatology 2012;56(Suppl):211A. Abstract 40.
- Search Google Scholar
- Export Citation
. Yao FY Mehta N Fix OK Down-stating of hepatocellular carcinoma to within Milan criteria prior to liver transplantation: comparison of long-term outcomes with tumors meeting Milan criteria without requiring down-staging [abstract]. Hepatology 2012; 56( Suppl): 211A. Abstract 40.
European Association For The Study of The Liver; European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943.
Orlando A, Leandro G, Olivo M et al.. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009;104:514–524.
Cho YK, Kim JK, Kim MY et al.. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453–459.
Fontana RJ, Hamidullah H, Nghiem H et al.. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl 2002;8:1165–1174.
Mazzaferro V, Battiston C, Perrone S et al.. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900–909.
Lu DS, Yu NC, Raman SS et al.. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005;41:1130–1137.
Varela M, Real MI, Burrel M et al.. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474–481.
Lencioni R, de Baere T, Burrel M et al.. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 2012;35:980–985.
Nicolini A, Martinetti L, Crespi S et al.. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:327–332.
Nicolini D, Svegliati-Baroni G, Candelari R et al.. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 2013;19:5622–5632.
Graziadei IW, Sandmueller H, Waldenberger P et al.. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557–563.
Maddala YK, Stadheim L, Andrews JC et al.. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004;10:449–455.
Chapman WC, Majella Doyle MB, Stuart JE et al.. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248:617–625.
Majno PE, Adam R, Bismuth H et al.. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688–701; discussion 701-683.
Hucke F, Sieghart W, Pinter M et al.. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol 2014;60:118–126.
Lewandowski RJ, Kulik LM, Riaz A et al.. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920–1928.
Vouche M, Habib A, Ward TJ et al.. Unresectable solitary HCC not amenable to RFA: Multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60:192–201.
Salem R, Lewandowski RJ, Kulik L et al.. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497–507 e492.
Moreno-Luna LE, Yang JD, Sanchez W et al.. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013;36:714–723.
Salem R, Gilbertsen M, Butt Z et al.. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013;11:1358–1365 e1351.
Kudo M, Imanaka K, Chida N et al.. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117–2127.
Sansonno D, Lauletta G, Russi S et al.. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012;17:359–366.
Vitale A, Volk ML, Pastorelli D et al.. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010;51:165–173.
Vouche M, Kulik L, Atassi R et al.. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 +/- sorafenib. Hepatology 2013;58:1655–1666.
Truesdale AE, Caldwell SH, Shah NL et al.. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int 2011;24:991–998.
Frenette CT, Boktour M, Burroughs SG et al.. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int 2013;26:734–739.
Ravaioli M, Grazi GL, Piscaglia F et al.. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8:2547–2557.
De Luna W, Sze DY, Ahmed A et al.. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009;9:1158–1168.
Barakat O, Wood RP, Ozaki CF et al.. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl 2010;16:289–299.
Jang JW, You CR, Kim CW et al.. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010;31:415–423.